Several studies also address the possibility of interfering with T cell-mediated responses as a novel approach for treating NASH, such as PR-957 which can hinder endothelial MHC-II antigen presentation to CD4+ T cells (200), lycopene,which can suppress the recruitment of T cells as well as activation of M1 macrophages (201), and koumine which can reduce the percentages of Th1 and Th17 cells and increase Th2 and Treg cells in the liver (202). Here, CD4 is linked to metabolic dysfunction-associated steatohepatitis.